161 related articles for article (PubMed ID: 27825117)
21. Downregulation of miR-25 modulates non-small cell lung cancer cells by targeting CDC42.
Yang T; Chen T; Li Y; Gao L; Zhang S; Wang T; Chen M
Tumour Biol; 2015 Mar; 36(3):1903-11. PubMed ID: 25432132
[TBL] [Abstract][Full Text] [Related]
22. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis.
Song Z; Jia G; Ma P; Cang S
Life Sci; 2021 Jul; 276():119399. PubMed ID: 33781830
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
24. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-187-5p suppresses cancer cell progression in non-small cell lung cancer (NSCLC) through down-regulation of CYP1B1.
Mao M; Wu Z; Chen J
Biochem Biophys Res Commun; 2016 Sep; 478(2):649-55. PubMed ID: 27495872
[TBL] [Abstract][Full Text] [Related]
26. Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers.
Vinci S; Gelmini S; Pratesi N; Conti S; Malentacchi F; Simi L; Pazzagli M; Orlando C
Clin Chem Lab Med; 2011 Sep; 49(12):2073-80. PubMed ID: 21902575
[TBL] [Abstract][Full Text] [Related]
27. Rs895819 within miR-27a might be involved in development of non small cell lung cancer in the Chinese Han population.
Ma JY; Yan HJ; Yang ZH; Gu W
Asian Pac J Cancer Prev; 2015; 16(5):1939-44. PubMed ID: 25773791
[TBL] [Abstract][Full Text] [Related]
28. MiR-494 acts as a tumor promoter by targeting CASP2 in non-small cell lung cancer.
Zhang Q; Li Y; Zhao M; Lin H; Wang W; Li D; Cui W; Zhou C; Zhong J; Huang C
Sci Rep; 2019 Feb; 9(1):3008. PubMed ID: 30816202
[TBL] [Abstract][Full Text] [Related]
29. Association Between microRNA-125a rs12976445 C>T Polymorphism and 18F-Fluorodeoxyglucose (18FDG) Uptake: Clinical and Metabolic Response in Patients with Non-Small Cell Lung Cancer.
Zang Z; Guan W; Chen D; Han Y; Shi Z; Zhou J
Med Sci Monit; 2016 Nov; 22():4186-4192. PubMed ID: 27814341
[TBL] [Abstract][Full Text] [Related]
30. A common CD55 rs2564978 variant is associated with the susceptibility of non-small cell lung cancer.
Zhang Y; Zhang Z; Cao L; Lin J; Yang Z; Zhang X
Oncotarget; 2017 Jan; 8(4):6216-6221. PubMed ID: 28008159
[TBL] [Abstract][Full Text] [Related]
31. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
32. Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer.
Khandelwal A; Seam RK; Gupta M; Rana MK; Prakash H; Vasquez KM; Jain A
Cancer Sci; 2020 Mar; 111(3):826-839. PubMed ID: 31520555
[TBL] [Abstract][Full Text] [Related]
33. Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population.
Xu J; Yin Z; Gao W; Liu L; Yin Y; Liu P; Shu Y
PLoS One; 2013; 8(10):e77024. PubMed ID: 24146953
[TBL] [Abstract][Full Text] [Related]
34. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-153 expression and prognosis in non-small cell lung cancer.
Chen WJ; Zhang EN; Zhong ZK; Jiang MZ; Yang XF; Zhou DM; Wang XW
Int J Clin Exp Pathol; 2015; 8(7):8671-5. PubMed ID: 26339455
[TBL] [Abstract][Full Text] [Related]
36. Decreased microRNA-224 and its clinical significance in non-small cell lung cancer patients.
Zhu D; Chen H; Yang X; Chen W; Wang L; Xu J; Yu L
Diagn Pathol; 2014 Nov; 9():198. PubMed ID: 25410592
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
Hua L; Zhu G; Wei J
Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression.
Zheng J; Zhang Y; Cai S; Dong L; Hu X; Chen MB; Zhu YH
Cancer Lett; 2020 Apr; 476():129-139. PubMed ID: 32081805
[TBL] [Abstract][Full Text] [Related]
39. Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
Qiu F; Yang L; Ling X; Yang R; Yang X; Zhang L; Fang W; Xie C; Huang D; Zhou Y; Lu J
Clin Cancer Res; 2015 Apr; 21(7):1602-13. PubMed ID: 25614447
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-383 is a tumor suppressor and potential prognostic biomarker in human non-small cell lung caner.
Shang Y; Zang A; Li J; Jia Y; Li X; Zhang L; Huo R; Yang J; Feng J; Ge K; Yang Y; Zhang Y; Jiang J
Biomed Pharmacother; 2016 Oct; 83():1175-1181. PubMed ID: 27551765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
